Cardiology
Partner With Us
Advertisement
Conexiant chevron_right Cardiology chevron_right BMI Influences Antiplatelet Therapy Outcomes in Patients Who Experienced AMI
From the Journals

BMI Influences Antiplatelet Therapy Outcomes in Patients Who Experienced AMI

Deescalation from ticagrelor to clopidogrel after PCI showed significantly better outcomes in AMI patients with BMI < 28, primarily through reduced bleeding risk

Conexiant
article Full Article subject Summary summarize Notecard
  1. De-escalation of antiplatelet therapy may have varying outcomes based on BMI.
  2. Patients with BMI < 28 experienced a 46% reduction in adverse events, mainly due to fewer bleeding complications.
  3. No statistically significant benefit was observed in patients with BMI ≥ 28.
  4. The study's limitations include its post hoc nature and reliance on baseline BMI without tracking changes over time.
  5. The findings caution against a definitive interpretation of the BMI threshold of 28.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.